DELAYED GASTRIC TRANSIT TIME OF CAPSULE ENDOSCOPY FOR PATIENTS WITH ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Yutaka Saito

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

A retrospective study of 335 capsule endoscopy examinations in stem cell transplant patients found that Letermovir administration was associated with significantly higher rates of gastric retention compared to controls (13.4% vs 5.7%, p=0.0150).

KEY POINTS

- Among 335 capsule endoscopy examinations performed in allogeneic stem cell transplant patients between July 2005 and July 2022, gastric retention (gastric transit time >390 minutes) occurred in 9.0% overall.
- Patients receiving Letermovir (142 examinations, 42.4% of total) had significantly higher gastric retention rates than controls (13.4% vs 5.7%, p=0.0150).
- The authors observed an increasing ratio of gastric retention after late 2018, coinciding with Letermovir introduction at their institution.
- The authors suggest that Letermovir might potentially cause gastric retention and propose endoscopic assistance to transport retained capsules as a potential solution.
- This material is relevant for gastroenterologists and hematologists managing stem cell transplant patients undergoing capsule endoscopy for suspected GVHD or CMV colitis.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/d6898732-743b-11ee-98bd-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.